MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Akebia Therapeutics Inc

Cerrado

SectorSanidad

3.93 -1.01

Resumen

Variación precio

24h

Actual

Mínimo

3.91

Máximo

4.04

Métricas clave

By Trading Economics

Ingresos

29M

6.1M

Ventas

11M

57M

Margen de beneficios

10.66

Empleados

181

EBITDA

20M

14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+88.44% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

342M

953M

Apertura anterior

4.94

Cierre anterior

3.93

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

174 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Akebia Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jul 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Principales Movimientos del Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Ganancias

BASF Cuts Outlook on Global Economy Uncertainty

11 jul 2025, 21:45 UTC

Charlas de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Charlas de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Charlas de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Charlas de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Charlas de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Charlas de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Ganancias

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Charlas de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Ganancias

BASF Will Publish Half-Year Results on July 30

11 jul 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 jul 2025, 16:04 UTC

Charlas de Mercado

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 jul 2025, 16:03 UTC

Ganancias

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 jul 2025, 16:02 UTC

Ganancias

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 jul 2025, 16:01 UTC

Ganancias

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 jul 2025, 16:00 UTC

Ganancias

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 jul 2025, 15:59 UTC

Ganancias

BASF Cuts 2025 Earnings View

11 jul 2025, 15:58 UTC

Ganancias

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 jul 2025, 15:57 UTC

Ganancias

BASF 2Q EBIT Before Special Items EUR810M

11 jul 2025, 15:54 UTC

Ganancias

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 jul 2025, 15:54 UTC

Ganancias

BASF 2Q Sales Fell 2.1% on Year

11 jul 2025, 15:53 UTC

Ganancias

BASF 2Q Sales EUR15.77B

11 jul 2025, 15:52 UTC

Ganancias

BASF: This Was in Line With Consensus Estimates

11 jul 2025, 15:52 UTC

Ganancias

BASF 2Q Ebitda Before Special Items EUR1.77B

11 jul 2025, 15:49 UTC

Ganancias

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 jul 2025, 15:41 UTC

Charlas de Mercado

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Comparación entre iguales

Cambio de precio

Akebia Therapeutics Inc previsión

Precio Objetivo

By TipRanks

88.44% repunte

Estimación a 12 Meses

Media 7.5 USD  88.44%

Máximo 8 USD

Mínimo 7 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Akebia Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.345 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

174 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.